Yazar "Akyuz, Aydin" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Endocan may predict the presence of coronary slow flow and coronary artery disease
    (Assoc Medica Brasileira, 2024) Efe, Muhammet Mucip; Akyuz, Aydin; Aydin, Cihan; Demirkiran, Aykut; Alpsoy, Seref
    OBJECTIVE: Coronary artery disease (CAD) is frequent, but coronary slow flow (CSF) is a less common cardiovascular disease with a significant risk of mortality and morbidity. Endocan is a proinflammatory glycopeptide that has been investigated in cardiovascular diseases as well as some inflammatory diseases in recent years. We planned to compare the levels of endocan in both CAD and CSF in a similar population and examine the relationship of endocan with additional clinical variables. MATERIALS AND METHODS: In the trial, we included 169 consecutive subjects having a coronary angiography indication. According to the results of coronary angiography, 58 people were included in the CAD group, 52 were in the CSF group, and 59 people were in the control group. The control group includes those who did not have any lesions in their epicardial coronary arteries. Thrombolysis in myocardial infarction (TIMI)-frame counts (TFC) were calculated for all patients. RESULTS: Notably, 2.6% of the population in our study had CSF. Both the CAD (555 +/- 223 pg/mL) and CSF (559 +/- 234 pg/mL) groups had higher endocan levels than the control group (331 +/- 252 pg/mL) (p<0.001). There were similar endocan levels between the CAD and CSF groups. Endocan levels were shown to be favorably associated with mean TFC (r=0.267; p0.001). Serum endocan levels (particularly those above 450 pg/mL) and the presence of hyperlipidemia were the most important predictors of both CAD and CSF. CONCLUSION: Endocan levels are higher in CAD and CSF patients than in those with normal coronary arteries.
  • Küçük Resim Yok
    Öğe
    Serum chromogranin A levels are associated with the SYNTAX score in coronary artery disease
    (Assoc Medica Brasileira, 2023) Celikkol, Aliye; Demirkiran, Aykut; Aydin, Cihan; Akyuz, Aydin; Kaplangoray, Mustafa; Yilmaz, Ahsen; Efe, Muhammed Mucip
    OBJECTIVE: In this article, we investigated the association of chromogranin A with coronary artery disease.METHODS: Biochemical parameters and chromogranin A levels obtained from peripheral blood samples during coronary angiography were analyzed in 90 patients. Patients were classified into two groups, namely, SYNergy between PCI with TAXUS and Cardiac Surgery score >= 1 (n=45) and SYNergy between PCI with TAXUS and Cardiac Surgery score=0 (n=45). This is a cross-sectional, prospective study. RESULTS: Serum chromogranin A levels were significantly higher in the group with SYNergy between PCI with TAXUS and Cardiac Surgery score >= 1 compared to the group with SYNergy between PCI with TAXUS and Cardiac Surgery score=0 (1381.5 +/- 418.9 ng/mL and 1121.2 +/- 290.7 ng/mL, respectively; p=0.002). Serum chromogranin A levels were correlated with SYNergy between PCI with TAXUS and Cardiac Surgery score (r=0.556, p<0.04). ROC analysis showed that the area under the curve for serum chromogranin A levels was 0.687 (p=0.007), and the best cutoff value of 1,131 ng/mL had a sensitivity of 67% and a specificity of 65% for the prediction of coronary artery disease.CONCLUSION: Serum chromogranin A levels were increased in coronary artery disease patients with SYNergy between PCI with TAXUS and Cardiac Surgery score >= 1. Increasing serum chromogranin A levels are proportional to the SYNergy between PCI with TAXUS and Cardiac Surgery score.KEYWORDS: Chromogranin A. Coronary artery disease. Hypertension.
  • Küçük Resim
    Öğe
    Ten-Year Outcomes Following Revascularization Strategies for Non-ST-Segment Elevation Myocardial Infarction and Multivessel Disease
    (Kare Publ, 2025) Demirkiran, Aykut; Aydin, Cihan; Akyuz, Aydin; Alpsoy, Seref
    Objective: There remain conflicting recommendations regarding revascularization strategies for patients with non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel disease (MVD). This study aimed to compare the long-term outcomes of different revascularization strategies. Method: Patients with similar characteristics were categorized into three groups: immediate complete revascularization (ICR), staged complete revascularization (SCR), and non-complete revascularization (NCR). The SCR group was further divided based on the time interval between the index and staged procedures: SCR <= 24 hours and SCR > 24 hours. Cardiac composite outcomes included the total number of cardiac deaths and recurrent myocardial infarction during the follow-up period. Results: Out of 14,511 screened patients, 316 were included in the analysis. The results showed a significant difference in risk between SCR and ICR (hazard ratio [HR] (95% confidence interval [CI]): 0.27 (0.15-0.47); P = 0.001). There was no significant difference between NCR and SCR (HR (95% CI): 1.06 (0.61-1.84); P = 0.832). The SCR group was divided into two groups based on the time interval from the first to the second procedure (time interval [TI] <= 24 hours in the SCR1 group, and TI > 24 hours in the SCR2 group). The frequency of cardiac composite outcomes was lower in SCR1 compared to SCR2 (16.7% vs. 47.1%; P = 0.038). Conclusion: Our findings support the use of ICR and SCR completed within 24 hours due to their favorable long-term outcomes in patients with MVD and NSTEMI.